chr12-42465080-G-C
Variant summary
Our verdict is Benign. Variant got -17 ACMG points: 0P and 17B. BP4_StrongBP6_Very_StrongBP7BS2
The NM_153026.3(PRICKLE1):āc.954C>Gā(p.Ser318Ser) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000484 in 1,567,294 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā ā ). Synonymous variant affecting the same amino acid position (i.e. S318S) has been classified as Likely benign.
Frequency
Consequence
NM_153026.3 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PRICKLE1 | NM_153026.3 | c.954C>G | p.Ser318Ser | synonymous_variant | 7/8 | ENST00000345127.9 | NP_694571.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PRICKLE1 | ENST00000345127.9 | c.954C>G | p.Ser318Ser | synonymous_variant | 7/8 | 1 | NM_153026.3 | ENSP00000345064.3 |
Frequencies
GnomAD3 genomes AF: 0.00267 AC: 406AN: 152144Hom.: 2 Cov.: 32
GnomAD3 exomes AF: 0.000786 AC: 164AN: 208574Hom.: 0 AF XY: 0.000594 AC XY: 66AN XY: 111052
GnomAD4 exome AF: 0.000249 AC: 353AN: 1415032Hom.: 2 Cov.: 32 AF XY: 0.000229 AC XY: 160AN XY: 699730
GnomAD4 genome AF: 0.00267 AC: 406AN: 152262Hom.: 2 Cov.: 32 AF XY: 0.00262 AC XY: 195AN XY: 74440
ClinVar
Submissions by phenotype
not specified Benign:4
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Nov 29, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Oct 28, 2013 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 20, 2015 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 28, 2016 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
not provided Benign:2
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Epilepsy, progressive myoclonic, 1B Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at